ArticleInternational journal of nanomedicine2026
A Porphyrinic Covalent Organic Polymer Nanoplatform for Carborane Delivery and Multifunctional Imaging-Guided Boron Neutron Capture Therapy of Breast Cancer.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The advancement of boron neutron capture therapy (BNCT) is critically dependent on the development of efficient and traceable boron delivery agents. Methods: We designed and synthesized a porphyrin-based covalent organic polymer (T-COP) loaded with ortho-carborane (o-CB) and surface-functionalized with DSPE-PEG Results: The resulting nanocomposite exhibits a high boron content (28.82 wt%), excellent colloidal stability, and pronounced fluorescence derived from the porphyrin building blocks, thereby enabling real-time tracking. In vitro, T-COP@o-CB NPs have outstanding biocompatibility, efficient cellular uptake, and prolonged intracellular retention in 4T1 breast cancer cells. In vivo fluorescence imaging confirms effective tumor localization and retention following intratumoral injection. Most notably, in a subcutaneous breast cancer mouse model, the T-COP@o-CB NPs with thermal neutron irradiation achieve 73.04% tumor inhibition compared to all control groups, while exhibiting no significant systemic toxicity as validated by body weight monitoring and histopathological analysis. Conclusion: This work presents a promising theranostic platform that combines high boron loading, inherent self-imaging capability, and effective tumor inhibition, offering a new strategy for precise and enhanced BNCT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.